This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alcon (ALC) and Oruka Therapeutics (ORKA)

Tipranks - Tipranks - Tue May 26, 10:52PM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alcon (ALC) and Oruka Therapeutics (ORKA).

Memorial Day Sale – Claim 70% Off TipRanks

Alcon (ALC)

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Alcon on May 21 and set a price target of $70.00. The company’s shares closed last Friday at $67.78.

According to TipRanks.com, Stephan is a 3-star analyst with an average return of 2.7% and a 39.1% success rate. Stephan covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, TransMedics Group, and Alphatec Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $91.62 average price target, a 35.0% upside from current levels. In a report issued on May 7, TipRanks – OpenAI also downgraded the stock to Hold with a CHF54.00 price target.

See today’s best-performing stocks on TipRanks >>

Oruka Therapeutics (ORKA)

In a report issued on May 23, Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics, with a price target of $125.00. The company’s shares closed last Friday at $60.61.

According to TipRanks.com, Slutsky is a top 100 analyst with an average return of 43.6% and a 52.3% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ArriVent BioPharma, Inc., and Abivax SA Sponsored ADR. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Oruka Therapeutics with a $137.25 average price target, implying a 132.7% upside from current levels. In a report issued on May 13, TD Cowen also maintained a Buy rating on the stock.

Read More on ALC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).